EFFECTS OF AVEMAR® TREATMENT ON QUALITY OF LIFE IN TERMINAL LUNG CANCER

 

Back to Clinical pages Print this page

 

Statistical evaluation of EORTC QLQ-C30 questionnaires

Center: Korányi National Institute of Tbc and Pulmonology, Budapest
Principal investigator: Dr. Zoltán Ajkay MD, General Director of Institute
Duration of study: 1999-2000
Number of patients: 17
Mean duration of Avemar treatment: 7.9 months
Diagnosis: SCLC (4 pts); NSCLC (13 pts)
Treatments: chemo- and radiotherapy (5 pts); chemotherapy alone (9 pts); palliative therapy (3 pts).
 

 

Results

 

 Quality components

Functional scales Significancy
Physical functions  N.S
Daily activity at home  N.S.
Emotional functions  N.S.
Cognitive functions  N.S.
Social functions P<0.018
Global state of health P<0.003

Symptomatic scales
Fatigue P<0.023
Nausea, vomiting N.S.
Pain N.S.
Dyspnoe N.S.
Insomnia N.S.
Asitia N.S.
 
Constipation P<0,045
Diarrhoea N.S.
Financial problems N.S.

  

Conclusions: Supportive Avemar treament of terminal lung cancer patients resulted in significant improvements of several components of quality of life.

 

Back to Clinical pages

 Print this page

.       Powered by webEFEKTs.